Targeting YAP/TAZ-TEAD signaling as a therapeutic approach in head and neck squamous cell carcinoma
Cancer Letters · 2025-03 · 612 · 217467
DOI: 10.1016/j.canlet.2025.217467 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2025-03. Verfasst von Kuniaki Sato und 11 weiteren Autor:innen. Beteiligte Einrichtung: Moores Cancer Center, University of California San Diego, La Jolla, CA, USA; Department of Pharmacology, University of California San Diego, La Jolla…. Hauptthemen laut MEDLINE: Transcription Factors, Head and Neck Neoplasms, Adaptor Proteins, Signal Transducing, DNA-Binding Proteins. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDCR NIH HHS, NCI NIH HHS, NIDCD NIH HHS.
Abstract (Originalsprache)
Genetic alterations in Hippo pathway and the consequent activation of YAP/TAZ-TEAD are frequently observed in HPV-negative head and neck squamous cell carcinoma (HNSCC) patients. These include loss-of-function mutation and/or copy number loss of FAT1, and amplification of YAP1 and WWTR1 (encoding TAZ), thus raising the possibility that HNSCC cells may be dependent on YAP/TAZ-TEAD-mediated transcriptional programs. In this regard, the recent development of small molecule TEAD inhibitors (smTEADi) provides an opportunity to therapeutically target Hippo pathway dysregulation in human malignancies. This prompted us to explore the potential benefit of pharmacologically targeting the YAP/TAZ-TEAD axis in this disease. Here, we provide the pre-clinical evidence for the antitumor activity of novel smTEADi, SW-682 in HPV-negative HNSCC. By the use of multiple complementary experimental approaches, including siRNA knockdown, expression of a genetically encoded TEAD inhibitor peptide (pTEADi), and SW-682, we revealed that disruption of YAP/TAZ-TEAD interaction suppresses YAP/TAZ-TEAD-dependent target gene transcription and growth of HNSCC tumors. HNSCC cells with genetic alterations in FAT1 were more sensitive to TEADi compared to FAT1-wild type cells. Mechanistically, TEADi suppressed cell cycle progression and promoted the expression of terminal differentiation gene programs, resulting in tumor growth inhibition. A HNSCC-specific TEADi target gene set was defined from RNA-seq data, which is highly expressed in HNSCC tissues and predicts poor prognosis of HPV-negative HNSCC patients. Our results underscore that YAP/TAZ-TEAD-mediated growth-promoting programs represent a vulnerability in HPV-negative HNSCC, thus providing a pre-clinical rationale for the future evaluation of YAP/TAZ-TEAD targeting strategies as a therapeutic approach for HPV-negative HNSCC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Moores Cancer Center, University of California San Diego, La Jolla, CA, USA; Department of Pharmacology, University of California San Diego, La Jolla, CA, USA.
- Moores Cancer Center, University of California San Diego, La Jolla, CA, USA; Department of Otolaryngology-Head and Neck Surgery, UC San Diego Health, La Jolla, CA, USA.
- Laboratory of Cellular and Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
- SpringWorks Therapeutics, Inc., Stamford, CT, USA.
- Moores Cancer Center, University of California San Diego, La Jolla, CA, USA; Department of Pharmacology, University of California San Diego, La Jolla, CA, USA. Electronic address: sgutkind@health.ucsd.edu.
Förderung
- NIDCR NIH HHS
- NCI NIH HHS
- NIDCD NIH HHS
- NIGMS NIH HHS
- National Institutes of Health
- Stand Up To Cancer
- United States - Israel Binational Science Foundation
- Bloom's Syndrome Foundation
Zitieren
APA
Sato, K., Faraji, F., Cervantes-Villagrana, R. D., Wu, X., Koshizuka, K., Ishikawa, T., Iglesias-Bartolome, R., Chen, L., Miliani de Marval, P. L., Gwaltney, S. L., Adler, B., & Gutkind, J. S. (2025). Targeting YAP/TAZ-TEAD signaling as a therapeutic approach in head and neck squamous cell carcinoma. Cancer Letters, 612, 217467. https://doi.org/10.1016/j.canlet.2025.217467
Vancouver
Sato K, Faraji F, Cervantes-Villagrana RD, Wu X, Koshizuka K, Ishikawa T, et al. Targeting YAP/TAZ-TEAD signaling as a therapeutic approach in head and neck squamous cell carcinoma. Cancer Letters. 2025;612:217467. doi:10.1016/j.canlet.2025.217467
BibTeX
@article{Sato2025,
author = {Sato, Kuniaki and Faraji, Farhoud and Cervantes-Villagrana, Rodolfo Daniel and Wu, Xingyu and Koshizuka, Keiichi and Ishikawa, Tomohiko and Iglesias-Bartolome, Ramiro and Chen, Lei and Miliani de Marval, Paula L and Gwaltney, Stephen L and Adler, Benjamin and Gutkind, J Silvio},
title = {Targeting YAP/TAZ-TEAD signaling as a therapeutic approach in head and neck squamous cell carcinoma},
journal = {Cancer Letters},
year = {2025},
volume = {612},
pages = {217467},
doi = {10.1016/j.canlet.2025.217467}
}
EUVIMED